This inventor holds 3 USPTO granted patents. Top assignees: Sociedad Espanola De Especialidades Farmacotera Peuticas, Sociedad Espanola De Especialidades Terepeuticas, S.a., Other. Active years: 1989-1992.
Company Filing History:
1 out of 1 
1 out of 1 
1 out of 834,411 Years Active: 1989-1992
Title: The Innovative Contributions of Pedro P Lloveras
Introduction
Pedro P Lloveras is a notable inventor based in Barcelona, Spain. He has made significant contributions to the field of pharmaceuticals, particularly in the development of vasodilatory agents. With a total of 3 patents to his name, Lloveras has demonstrated a commitment to advancing medical science through his innovative work.
Latest Patents
Lloveras's latest patents include the development of vasodilatory dihydrodibenzocycloheptyliden-ethylpiperazine derivatives. These compounds are characterized by a specific formula that includes various substituents, such as --CH.dbd.CH.sub.2 and --CO.sub.2 C.sub.2 H.sub.5. Another significant patent involves a dihydrodibenzocycloheptyliden-ethyl-piperazine derivative, which is also designed for pharmaceutical applications. These compounds are particularly useful in treating pathologies that respond to vasodilatory agents.
Career Highlights
Throughout his career, Lloveras has worked with prominent companies in the pharmaceutical industry. Notable among these are Sociedad Española de Especialidades Terapéuticas and Sociedad Española de Especialidades Farmacoterapéuticas. His work in these organizations has allowed him to contribute to the development of innovative therapeutic solutions.
Collaborations
Lloveras has collaborated with esteemed colleagues, including Xavier D Cirera and Romeo R Andreoli. These partnerships have further enriched his research and development efforts in the pharmaceutical field.
Conclusion
Pedro P Lloveras stands out as a significant figure in the realm of pharmaceutical innovation. His contributions through patents and collaborations highlight his dedication to improving medical treatments. His work continues to influence the development of effective vasodilatory agents.